<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04556773</url>
  </required_header>
  <id_info>
    <org_study_id>D967JC00002</org_study_id>
    <nct_id>NCT04556773</nct_id>
  </id_info>
  <brief_title>A Phase 1b Study of T-DXd Combinations in HER2-low Advanced or Metastatic Breast Cancer</brief_title>
  <acronym>DB-08</acronym>
  <official_title>A Phase 1b Multicentre, Open-label, Modular, Dose-finding and Dose-expansion Study to Explore the Safety, Tolerability, Pharmacokinetics and Anti-tumour Activity of Trastuzumab Deruxtecan (T-DXd) in Combination With Other Anti-cancer Agents in Patients With Metastatic HER2-low Breast Cancer (DESTINY-Breast08)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Daiichi Sankyo Company, Limited</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      DESTINY-Breast 08 will investigate the safety, tolerability, PK and preliminary anti-tumour&#xD;
      activity of T-DXd in combination with other therapies in patients with Metastatic HER2-low&#xD;
      Advanced or Metastatic Breast Cancer&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is modular in design allowing assessment of the safety, tolerability, PK and&#xD;
      preliminary anti-tumour activity of T-DXd in combination with other therapies.&#xD;
      Combination-treatment modules will have 2 parts: a dose-finding phase (Part 1), and a dose&#xD;
      expansion phase (Part 2); the Part 2 dose-expansion phase will use the RP2D determined in&#xD;
      Part 1.&#xD;
&#xD;
      The target population of interest in this study is patients with HER2-low (IHC 1+ or IHC&#xD;
      2+/ISH -) (as per ASCO/CAP 2018 guidelines) advanced/MBC. Part 1 of each module will enroll&#xD;
      patients with locally confirmed HER2-low advanced/MBC in second-line or later (â‰¥ 2L) settings&#xD;
&#xD;
      Part 2 of each module will enroll patients with HER2-low MBC who have either not received&#xD;
      prior treatment, or received only 1 prior treatment (depending on the module-specific&#xD;
      exclusion criteria) for advanced/metastatic disease&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 17, 2020</start_date>
  <completion_date type="Anticipated">August 28, 2023</completion_date>
  <primary_completion_date type="Anticipated">August 28, 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>The study will initially consist of 5 treatment modules, each of which includes T-DXd in combination with other anti-cancer agents. Each module will have 2 parts: a dose-finding phase (Part 1) and a dose-expansion phase (Part 2). The Part 2 dose-expansion phase will use the recommended Phase 2 dose (RP2D) for the combination, either as determined in Part 1 or from another clinical study if appropriate. For each module, patients will be centrally assigned to one of the open modules, as per the module specific criteria.&#xD;
In addition to safety and tolerability, this study will also assess ORR, PFS, DoR, and OS for each treatment combination.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Occurrence of adverse events (AEs)- Part 1</measure>
    <time_frame>Up to follow-up period, approximately 24 months</time_frame>
    <description>Occurrence of AEs in Part 1 graded according to NCI CTCAE v5.0</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Occurrence of serious adverse events (SAEs)- Part 1</measure>
    <time_frame>Up to follow-up period, approximately 24 months</time_frame>
    <description>Occurrence of SAEs in Part 1 graded according to NCI CTCAE v5.0</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Occurrence of adverse events (AEs)- Part 2</measure>
    <time_frame>Up to follow-up period, approximately 24 months</time_frame>
    <description>Occurrence of AEs in Part 2 graded according to NCI CTCAE v5.0</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Occurrence of serious adverse events (SAEs)- Part 2</measure>
    <time_frame>Up to follow-up period, approximately 24 months</time_frame>
    <description>Occurrence of SAEs in Part 2 graded according to NCI CTCAE v5.0</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate (ORR)- Part 2</measure>
    <time_frame>Until progression, assessed up to approximately 24 months</time_frame>
    <description>ORR defined as the proportion of patients who have a confirmed CR or PR, as determined by the investigator at local site per RECIST 1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival (PFS)- Part 2</measure>
    <time_frame>Until progression or death, assessed up to approximately 24 months</time_frame>
    <description>PFS defined as time from the date of first dose until the date of progression as determined by the investigator at local site per RECIST 1.1, or death due to any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DoR)- Part 2</measure>
    <time_frame>Until progression or death, assessed up to approximately 24 months</time_frame>
    <description>DoR defined as time from the date of first documented response (which is subsequently confirmed) until the date of documented progression or death in the absence of disease progression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)- Part 2</measure>
    <time_frame>Until death, assessed up to approximately 24 months</time_frame>
    <description>OS defined as time from the date of first dose until the date of death by any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum concentration of T-DXd, total anti-HER2 antibody and MAAA-1181a</measure>
    <time_frame>While on study drug up to study completion, approximately 24 months</time_frame>
    <description>Determination of trastuzumab deruxtecan concentration in serum at different time points after trastuzumab deruxtecan administration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity of trastuzumab deruxtecan</measure>
    <time_frame>Up to follow-up period, approximately 24 months</time_frame>
    <description>Percentage of patients who develop ADA for trastuzumab deruxtecan</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Concentration of durvalumab</measure>
    <time_frame>While on study drug up to study completion, approximately 24 months</time_frame>
    <description>Determination of durvalumab concentration in serum at different time points after administration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity of durvalumab</measure>
    <time_frame>Up to follow-up period, approximately 24 months</time_frame>
    <description>Percentage of patients who develop ADAs for durvalumab</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">185</enrollment>
  <condition>Metastatic Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Module 1: T-DXd + capecitabine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>T-DXd: 5.4 mg/kg Q3W, intravenous use Capecitabine: 1000mg/m2 BID, days 1-14 Q3W, oral use</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Module 2: T-DXd + durvalumab + paclitaxel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>T-DXd: 5.4 mg/kg Q3W, intravenous use Durvalumab: 1120 mg Q3W, intravenous use Paclitaxel: 80 mg/m2 QW in 3-week cycles, intravenous use</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Module 3: T-DXd + capivasertib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>T-DXd: 5.4 mg/kg Q3W, intravenous use Capivasertib: 400 mg BID, oral use</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Module 4: T-DXd + anastrozole</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>T-DXd: 5.4 mg/kg Q3W, intravenous use Anastrozole: 1 mg daily, oral</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Module 5: T-DXd + fulvestrant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>T-DXd: 5.4 mg/kg Q3W, intravenous use Fulvestrant: 500 mg Q4W, intramuscular use</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Trastuzumab deruxtecan</intervention_name>
    <description>T-DXd: administered as an IV infusion</description>
    <arm_group_label>Module 1: T-DXd + capecitabine</arm_group_label>
    <arm_group_label>Module 2: T-DXd + durvalumab + paclitaxel</arm_group_label>
    <arm_group_label>Module 3: T-DXd + capivasertib</arm_group_label>
    <arm_group_label>Module 4: T-DXd + anastrozole</arm_group_label>
    <arm_group_label>Module 5: T-DXd + fulvestrant</arm_group_label>
    <other_name>DS-8201a, T-DXd</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Durvalumab</intervention_name>
    <description>Durvalumab: administered as an IV infusion</description>
    <arm_group_label>Module 2: T-DXd + durvalumab + paclitaxel</arm_group_label>
    <other_name>MEDI4736</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
    <description>Paclitaxel: administered as an IV infusion</description>
    <arm_group_label>Module 2: T-DXd + durvalumab + paclitaxel</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Capivasertib</intervention_name>
    <description>Capivasertib: administered orally</description>
    <arm_group_label>Module 3: T-DXd + capivasertib</arm_group_label>
    <other_name>AZD5363</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anastrozole</intervention_name>
    <description>Anastrozole: administered orally</description>
    <arm_group_label>Module 4: T-DXd + anastrozole</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fulvestrant</intervention_name>
    <description>Fulvestrant: administered as an IM injection</description>
    <arm_group_label>Module 5: T-DXd + fulvestrant</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Capecitabine</intervention_name>
    <description>Capecitabine: administered orally</description>
    <arm_group_label>Module 1: T-DXd + capecitabine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          -  Patients must be at least 18 years of age&#xD;
&#xD;
          -  Male or female patients who have pathologically documented breast cancer that:&#xD;
&#xD;
               1. Has a history of HER2-low expression, defined as IHC 2+/ISH- or IHC 1+ (ISH- or&#xD;
                  untested) with a validated assay&#xD;
&#xD;
               2. Is documented as HR+ (either ER and/or PgR positive [ER or PgR â‰¥1%]) or ER and&#xD;
                  PgR negative (ER and PgR &lt;1%) per ASCO/CAP guidelines in the metastatic setting&#xD;
&#xD;
          -  Patient must have adequate tumor sample for biomarker assessment&#xD;
&#xD;
          -  ECOG Performance Status of 0 or 1&#xD;
&#xD;
        For patients with HR+ disease:&#xD;
&#xD;
        Part 1: At least 1 prior treatment line of ET with or without a targeted therapy (such as&#xD;
        CDK4/6, mTOR or PI3-K inhibitors), and at least 1 prior line of chemotherapy for MBC are&#xD;
        required.&#xD;
&#xD;
        Part 2: Only 1 prior treatment line of ET with or without a targeted therapy (such as&#xD;
        CDK4/6, mTOR or PI3-K inhibitors) for MBC is allowed. No prior chemotherapy in the&#xD;
        metastatic setting is allowed. Note there are no patients with HR+ disease in Part 2 of&#xD;
        Modules 2 and 3.&#xD;
&#xD;
        For patients with HR- disease:&#xD;
&#xD;
        Part 1: At least 1 prior line of chemotherapy for MBC is required. Note there are no&#xD;
        patients with HR- disease in Part 1 of Modules 4 and 5.&#xD;
&#xD;
        Part 2: For Module 2, no prior lines of therapy for MBC are allowed, and for Modules 1 and&#xD;
        3, only 1 prior line of chemotherapy for MBC is allowed. Note there are no patients with&#xD;
        HR- disease in Part 2 of Modules 4 and 5.&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          -  Uncontrolled intercurrent illness&#xD;
&#xD;
          -  Uncontrolled or siginificant cardiovascular disease&#xD;
&#xD;
          -  History of (non-infectious) ILD/pneumonitis that required steroids, has current&#xD;
             ILD/pneumonitis, or where suspected ILD/pneumonitis cannot be ruled out by imaging at&#xD;
             screening.&#xD;
&#xD;
          -  Lung-specific intercurrent clinically significant illnesses&#xD;
&#xD;
          -  Has spinal cord compression or clinically active central nervous system metastases&#xD;
&#xD;
          -  Active primary immunodeficiency&#xD;
&#xD;
          -  Uncontrolled infection requiring IV antibiotics, antivirals, or antifungals&#xD;
&#xD;
          -  Prior treatment with ADC that comprises of an exatecan derivative that is a&#xD;
             topoisomerase I inhibitor.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>AstraZeneca Clinical Study Information Center</last_name>
    <phone>1-877-240-9479</phone>
    <email>information.center@astrazeneca.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>AZ Breast Cancer Study Navigators</last_name>
    <phone>+1-877-400-4656</phone>
    <email>AstraZeneca@CareboxHealth.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Saint Paul</city>
        <state>Minnesota</state>
        <zip>55101</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ridgewood</city>
        <state>New Jersey</state>
        <zip>07450</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Commack</city>
        <state>New York</state>
        <zip>11725</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10028</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599-7081</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Chattanooga</city>
        <state>Tennessee</state>
        <zip>37404</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Germantown</city>
        <state>Tennessee</state>
        <zip>38138</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>East Melbourne</city>
        <zip>3002</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Westmead</city>
        <zip>2145</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Edegem</city>
        <zip>2650</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ottignies</city>
        <zip>1340</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>BrasÃ­lia</city>
        <zip>70200-730</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Goiania</city>
        <zip>74605-070</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Porto Alegre</city>
        <zip>90035-003</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Porto Alegre</city>
        <zip>90110-270</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sao Paulo</city>
        <zip>01317-001</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sao Paulo</city>
        <zip>04543-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>SÃ£o Paulo</city>
        <zip>03102-002</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>SÃ£o Paulo</city>
        <zip>04538-132</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kelowna</city>
        <state>British Columbia</state>
        <zip>V1Y 5L3</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Quebec</city>
        <zip>G1R 2J6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Villejuif Cedex</city>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Seoul</city>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Seoul</city>
        <zip>03722</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Seoul</city>
        <zip>05505</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Seoul</city>
        <zip>06351</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Merida</city>
        <zip>97000</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Moscow</city>
        <zip>115478</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Moscow</city>
        <zip>143442</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>194017</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>195271</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kaohsiung</city>
        <zip>82445</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Taichung</city>
        <zip>40443</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Taipei City</city>
        <zip>114</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Taipei</city>
        <zip>100</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Taipei</city>
        <zip>11217</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Taipei</city>
        <zip>235</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Taoyuan</city>
        <zip>333</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Belgium</country>
    <country>Brazil</country>
    <country>Canada</country>
    <country>France</country>
    <country>Korea, Republic of</country>
    <country>Mexico</country>
    <country>Russian Federation</country>
    <country>Taiwan</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://BreastCancerStudyLocator.com</url>
    <description>Related Info</description>
  </link>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>September 15, 2020</study_first_submitted>
  <study_first_submitted_qc>September 15, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 21, 2020</study_first_posted>
  <last_update_submitted>November 15, 2021</last_update_submitted>
  <last_update_submitted_qc>November 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Breast Cancer</keyword>
  <keyword>HER2-negative</keyword>
  <keyword>HER2-low</keyword>
  <keyword>Trastuzumab Deruxtecan</keyword>
  <keyword>T-DXd</keyword>
  <keyword>DS-8201a</keyword>
  <keyword>DESTINY-Breast08</keyword>
  <keyword>Anti-HER2 Antibody Drug Conjugate (ADC)</keyword>
  <keyword>Triple-negative breast cancer (TNBC)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Trastuzumab</mesh_term>
    <mesh_term>Durvalumab</mesh_term>
    <mesh_term>Fulvestrant</mesh_term>
    <mesh_term>Anastrozole</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_time_frame>AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.</ipd_time_frame>
    <ipd_access_criteria>When a request has been approved AstraZeneca will provide access to the deidentified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.</ipd_access_criteria>
    <ipd_url>https://astrazenecagroup-dt.pharmacm.com/DT/Home</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

